AP232 is a U2AF1-UHM inhibitor for leukemia research
**Background**
Leukemia is a malignant cancer of the blood and bone marrow characterized by the uncontrolled proliferation of abnormal white blood cells. Splicing factor mutations are frequently observed in various types of leukemia and play a critical role in the pathogenesis and progression of the disease. Among these, the U2 auxiliary factor 1 (U2AF1) is a key component of the spliceosome, and its homology motif (UHM) is essential for protein-protein interactions that regulate pre-mRNA splicing. Targeting the U2AF1-UHM domain presents a promising therapeutic strategy, particularly for cell lines carrying splicing factor mutations. In this context, we will introduce a selective U2AF1-UHM inhibitor – AP232.
**Definition**
AP232 dihydrochloride is a selective U2AF1-UHM inhibitor with an IC50 value of 7.96 μM. According to the AP232 description, this compound exhibits 2.8-24-fold selectivity against other UHM-containing proteins.
**In Vitro Studies**
The AP232 biological activity has been extensively evaluated in various leukemia models. In vitro studies demonstrated that AP232 dihydrochloride inhibits the U2 auxiliary factor homology motif of U2AF1 (U2AF1-UHM) with an IC50 of 7.96 μM, showing selectivity over RBM39-UHM, SPF45-UHM, PUF60-UHM, and U2AF2-UHM. In K562 cells, AP232 (40 μM) stabilizes endogenous full-length U2AF1 and reduces its sensitivity to Pronase. Furthermore, AP232 (72 h) inhibits cell growth across six leukemia cell lines, including MV4-11, NKM-1, K562, MOLM13, HNT-34, and MONO-MAC1.
Regarding cell cycle regulation, AP232 (5-30 μM; 24-48 h) disrupts the cell cycle of leukemia cells. Specifically, in NKM-1 cells, it increased the G2/M phase ratio at 48 h. In K562 cells, treatment at 24 h reduced the S phase and increased the sub-G1 phase, while treatment at 48 h increased the G1 phase and reduced the S and G2/M phases. Additionally, AP232 (20 μM; 2 h) reduces the proportion of functional lysosomes in NKM-1, K562, and MV4-11 cells. Notably, AP232 (10-30 μM; 48 h) inhibits AP232 autophagy in NKM-1 and K562 cells and impairs lysosome acidification. In conclusion, AP232 is a selective U2AF1-UHM inhibitor that exerts potent anti-leukemia activity by inducing cell cycle arrest and inhibiting autophagy.
Keywords
AP232, AP 232, AP-232, DNA/RNA Synthesis, Autophagy, U2AF1, UHM, Leukemia, Lysosome, MV4-11, NKM-1, K562, MOLM13, HNT-34, MONO-MAC1
References
**Background**
The ghrelin receptor, also known as the growth hormone secretagogue receptor (GHSR-1a), plays a critical role in the regulation of energy homeostasis, appetite, and growth hormone secretion. Ghrelin, the endogenous ligand for this receptor, is primarily produced in the stomach and acts as a potent orexigenic signal to increase food intake. Due to its influence on metabolic processes and appetite, the ghrelin receptor has become a significant therapeutic target for the treatment of obesity, type 2 diabetes, and other metabolic disorders. Developing selective inverse agonists that can reduce the constitutive activity of the receptor is a promising strategy for managing these conditions. In this context, we will introduce a potent ghrelin receptor inverse agonist – (S)-PF-5190457.
**Definition**
(S)-PF-5190457 is the S-enantiomer of PF-5190457 and serves as a potent and selective ghrelin receptor inverse agonist with a pKi value of 8.36.
**In Vitro and In Vivo Studies**
The (S)-PF-5190457 description identifies it as a small molecule with a molecular weight of 512.67 and a specific chemical structure defined by the (S)-PF-5190457 formula C29H32N6OS. Regarding (S)-PF-5190457 biological activity, the compound is designed to exhibit high selectivity for the ghrelin receptor over other related receptors, effectively suppressing the receptor’s basal activity. Research indicates that the parent compound, PF-5190457, is not only potent but also orally bioavailable, making it a strong clinical candidate for metabolic research. While specific cell line IC50 values for the S-enantiomer are typically derived from the racemic activity, the high pKi suggests strong binding affinity and efficacy in inhibiting ghrelin-mediated signaling. In conclusion, (S)-PF-5190457 is a highly selective ghrelin receptor inverse agonist that provides a valuable tool for studying metabolic regulation and appetite suppression.
Keywords
(S)-PF-5190457, (S)-PF-05190457, GHSR, Growth hormone secretagogue receptor, Ghrelin receptor, S-enantiomer of PF-5190457, ghrelin receptor, Inhibitor, inhibitor, inhibit
References
**Background**
P2X receptors are a family of ligand-gated ion channels activated by extracellular adenosine triphosphate (ATP), playing critical roles in various physiological processes, including neurotransmission, inflammation, and vascular tone regulation. Dysregulation of these receptors is often associated with pathological conditions such as glomerulonephritis and airway smooth muscle dysfunction. Specifically, the activation of P2X receptors can trigger cellular proliferation and ion exchange imbalances that contribute to tissue damage. Consequently, the development of potent P2X receptor antagonists is essential for understanding these signaling pathways and discovering potential therapeutic interventions. In this context, we will introduce a non-selective P2X receptor antagonist – PPADS tetrasodium.
**Definition**
PPADS tetrasodium is a non-selective P2X receptor antagonist that blocks recombinant P2X1, -2, -3, and -5 receptors with $\text{IC}_{50}$ values ranging from 1 to 2.6 $\mu\text{M}$.
**In Vitro and In Vivo Studies**
According to the PPADS tetrasodium description, this compound also blocks native $\text{P2Y}_2$-like ($\text{IC}_{50} \approx 0.9\text{ mM}$) and recombinant $\text{P2Y}_4$ ($\text{IC}_{50} \approx 15\text{ mM}$) receptors. Regarding PPADS tetrasodium in vitro activity, the compound (1-30 $\mu\text{M}$; 10-50 minutes) inhibits the reverse mode of the $\text{Na}^+/\text{Ca}^{2+}$ exchanger ($\text{NCX}_{\text{REV}}$) in guinea pig airway smooth muscle in a time- and concentration-dependent manner. In human P2X receptors, sensitivity varies by subtype, with the highest potency observed at hP2X1, -2, -3, -5, and -7Rs ($\text{IC}_{50} \approx 1\text{-}3\text{ }\mu\text{M}$) and a lower potency at hP2X4R ($\text{IC}_{50} \approx 30\text{ }\mu\text{M}$).
Furthermore, PPADS tetrasodium In Vivo studies have demonstrated its efficacy in renal models. In male Sprague-Dawley rats (160 to 200 g) with anti-Thy1 induced mesangial proliferative glomerulonephritis, PPADS tetrasodium was administered i.p. every 12 hours for 8 days at doses of 15, 30, and 60 mg/100g body weight (BW). The loading dose was doubled compared to subsequent injections. The results showed that the compound specifically and dose-dependently reduced early (day 3) glomerular mesangial cell (MC) proliferation without altering the proliferation of non-MC. For researchers seeking detailed PPADS tetrasodium technical information, these results highlight its potential in managing proliferative renal diseases. In conclusion, PPADS tetrasodium is a potent non-selective P2X receptor antagonist and $\text{NCX}_{\text{REV}}$ inhibitor.
Keywords
PPADS tetrasodium, 192575-19-2, P2X Receptor, Na+/Ca2+ Exchanger, P2XRs, guinea, pig, airway, smooth, muscle, exchanger, glomerular, mesangial, cell, ATP-sensitive
References
[1] Flores-Soto E, et al. PPADS, a P2X receptor antagonist, as a novel inhibitor of the reverse mode of the Na⁺/Ca²⁺ exchanger in guinea pig airway smooth muscle. Eur J Pharmacol. 2012 Jan 15;674(2-3):439-44.
[2] Huo H, et al. Mapping the binding site of the P2X receptor antagonist PPADS reveals the importance of orthosteric site charge and the cysteine-rich head region. J Biol Chem. 2018 Aug 17;293(33):12820-12831.
[3] Einfluss von ATP und seinen Derivaten auf die Aktivierung von Monozyten.
[4] Rost S, et al. P2 receptor antagonist PPADS inhibits mesangial cell proliferation in experimental mesangialproliferative glomerulonephritis. Kidney Int. 2002 Nov;62(5):1659-71.
**Background**
The development of sophisticated RNA nanostructures has opened new avenues in the fields of synthetic biology and precision medicine. RNA assemblies, characterized by their ability to organize molecules into specific spatial arrangements, are particularly valuable for studying intracellular molecular interactions and developing advanced delivery systems. Such DNA/RNA nanostructures are increasingly recognized as essential tools in cell and gene therapy (CGT) research, where precise control over molecular architecture can enhance therapeutic efficacy and targeting. To visualize and study these assemblies within the complex environment of living cells, high-performance fluorescent probes are required. In this context, we will introduce a red fluorophore designed for RNA aptamer labeling – DFAME.
**Definition**
DFAME is a red fluorophore with an excitation wavelength of 508 nm and an emission wavelength of 641 nm, used to label dimeric fluorescent RNA aptamers.
**In Vitro Studies**
According to the DFAME description, this compound is characterized by a molecular weight of 322.26 and the DFAME formula $\text{C}_{15}\text{H}_{12}\text{F}_2\text{N}_2\text{O}_4$. DFAME exhibits specific binding affinities for dimeric fluorescent RNA aptamers, specifically Beetroot and Corn. In vitro binding assays demonstrate that DFAME binds to the Beetroot aptamer with a dissociation constant ($K_d$) of 460 nM and to the Corn aptamer with a $K_d$ of 3600 nM. These interactions result in the formation of Beetroot-DFAME and Corn-DFAME complexes. These labeled aptamers can be further utilized to create multivalent RNA assemblies within living cells, providing a powerful method for the study of RNA nanostructures. By leveraging the DFAME biological activity, researchers can monitor the self-assembly of intracellular RNA complexes with high sensitivity. In conclusion, DFAME is a specialized red fluorophore that enables the visualization and construction of RNA nanostructures for biomedical research.
Keywords
DFAME, 1420815-55-9, Fluorescent Dye, fluorophore, Beetroot, Corn, dimeric fluorogenic aptamers, RNA assemblies, Inhibitor, inhibitor, inhibit
References
**Background**
Allergic rhinitis and asthma are prevalent inflammatory conditions characterized by the release of histamine, which triggers various physiological responses through the activation of histamine receptors. Among these, the histamine 1 (H1) receptor plays a pivotal role in mediating the allergic response, making it a primary target for therapeutic intervention. Beyond respiratory allergies, recent research has explored the potential of antihistamines in managing metabolic disorders and viral entry, including SARS-CoV-2. Understanding the diverse pharmacological profile of H1 antagonists is essential for developing comprehensive treatment strategies for airway remodeling and systemic metabolic dysfunction. In this context, we will introduce a potent and selective H1 receptor antagonist – Azelastine.
**Definition**
Azelastine is a potent and selective histamine 1 (H1) antagonist. According to the Azelastine technical information, it is utilized in the research of allergic rhinitis, asthma, diabetic hyperlipidemia, and SARS-CoV-2.
**In Vitro and In Vivo Studies**
The Azelastine biological activity has been demonstrated across various experimental models. In vitro studies using human nasal epithelial cells (HNEpC) showed that Azelastine (100 μM and 400 μM) significantly inhibited HNEpC proliferation over a 21-day incubation period, suggesting a potential role in combating airway remodeling. Furthermore, Western Blot analysis revealed that treatment with 100 μM Azelastine for 7 days significantly up-regulated the levels of H1R, M1R, and M3R in HNEpC.
Azelastine in vivo efficacy has been extensively evaluated in metabolic models. In diabetic hyperlipidemic male albino Wistar rats, oral administration of Azelastine (4 mg/kg; daily for 8 weeks) significantly reduced blood glucose, HbA1c, and serum alkaline phosphatase (ALP) and osteocalcin. This treatment also improved the lipid profile by decreasing LDL-c and increasing HDL-c, while downregulating apolipoprotein B and increasing apolipoprotein A expression. Additionally, the administration of Azelastine attenuated calcium deposition and aortic calcification in these models. In conclusion, Azelastine is a versatile H1 receptor antagonist with significant potential in treating allergic inflammation and modulating metabolic complications in diabetic hyperlipidemic states.
Keywords
Azelastine, 79307-93-0, Histamine Receptor, SARS-CoV, SARS coronavirus, antihistamine, allergic rhinitis, asthma, SARS-CoV-2, Inhibitor, inhibitor, inhibit
References
[1] Craig La Force. Review of the pharmacology, clinical efficacy, and safety of azelastine hydrochloridel. Expert Rev Clin Immunol. 2005 Jul;1(2):191-201.
[2] Mohamed M Elseweidy, et al. Azelastine a potent antihistamine agent, as hypolipidemic and modulator for aortic calcification in diabetic hyperlipidemic rats model. Arch Physiol Biochem. 2020 Jul 2;1-8.
[3] Carlos D. Zappia, et al. Azelastine potentiates antiasthmatic dexamethasone effect on a murine asthma model. Pharmacol Res Perspect. 2019 Dec; 7(6): e00531.
[4] Li Yang, et al. Identification of SARS-CoV-2 entry inhibitors among already approved drugs. Acta Pharmacol Sin. 2020 Oct 28 : 1–7.
[5] Shao-Cheng Liu, et al. Effect of budesonide and azelastine on histamine signaling regulation in human nasal epithelial cells. Eur Arch Otorhinolaryngol. 2017 Feb;274(2):845-853.
**Background**
Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that plays a critical role in signal transduction downstream of immunoreceptors, including the B-cell receptor (BCR) and Fc receptors. Dysregulation of Syk signaling is frequently associated with various inflammatory diseases and hematologic malignancies, particularly B-cell lymphomas and leukemias, where it promotes cell survival, proliferation, and migration. Due to its central position in these signaling pathways, Syk has become a high-priority therapeutic target for the development of targeted therapies in oncology and immunology. In this context, we will introduce a potent Syk inhibitor – Syk-IN-1.
**Definition**
Syk-IN-1 is a potent Syk inhibitor with an IC50 value of 35 nM. According to the Syk-IN-1 description, this compound serves as a powerful tool for modulating Syk-mediated signaling pathways in various biological models.
**In Vitro Studies**
The Syk-IN-1 biological activity has been extensively evaluated across multiple cell lines to determine its efficacy and selectivity. In vitro studies demonstrated significant antiproliferative activity against several human cancer cell lines. Specifically, when incubated for 3 days and assessed by WST-1 assay, Syk-IN-1 exhibited IC50 values of 25 nM in OCI-Ly10 cells, 105 nM in HBL1 cells, and 281 nM in TMD8 cells. Furthermore, the compound showed an inhibitory effect on ZAP70 in anti-CD3 stimulated human Jurkat T cells, with an IC50 of 2526 nM, as measured by SLP76 phosphorylation at Y128 via FACS analysis after a 30-minute preincubation. Regarding selectivity and toxicity, the compound showed an IC50 of 9020 nM against C57BL/6 mouse bone marrow cells (growth inhibition measured after 4 days of preincubation) and an IC50 of 25900 nM for the inhibition of human ERG expressed in CHO cells using an automated Qpatch clamp assay. These results, detailed in the Syk-IN-1 data sheet, highlight the compound’s potency in inhibiting Syk-driven proliferation in B-cell malignancy models. In conclusion, Syk-IN-1 is a potent and effective Syk inhibitor suitable for research into Syk-mediated cancer progression.
Keywords
Syk-IN-1, 1491150-77-6, Syk, Spleen tyrosine kinase, Inhibitor, inhibitor, inhibit
References
**Background**
Proteolysis-targeting chimeras (PROTACs) have emerged as a revolutionary class of bifunctional molecules designed to selectively degrade disease-causing proteins. Unlike traditional inhibitors that only block the active site of a protein, PROTACs exploit the cell’s endogenous ubiquitin-proteasome system to achieve complete protein removal. A typical PROTAC consists of two ligands—one targeting the protein of interest and another targeting an E3 ubiquitin ligase—connected by a chemical linker. The length and composition of this linker are critical, as they determine the spatial orientation and stability of the ternary complex formed between the target protein and the E3 ligase. In the context of cancer research, optimizing these linkers is essential for enhancing the degradation efficiency of oncogenic drivers. Therefore, we will introduce a versatile PEG-based linker – Pentaethylene glycol di(p-toluenesulfonate).
**Definition**
Pentaethylene glycol di(p-toluenesulfonate) is a PEG-based PROTAC linker used in the chemical synthesis of proteolysis-targeting chimeras. It features a molecular weight of 546.65 and a chemical formula of C24H34O10S2.
**In Vitro Studies**
The utility of this compound lies in its ability to serve as a flexible and hydrophilic bridge between two targeting ligands. According to the Pentaethylene glycol di(p-toluenesulfonate) description, this linker is specifically designed to facilitate the recruitment of an E3 ubiquitin ligase to a target protein, thereby promoting ubiquitination and subsequent proteasomal degradation. When evaluating Pentaethylene glycol di(p-toluenesulfonate) in vitro, researchers utilize its bifunctional tosylate groups to covalently attach the respective ligands through nucleophilic substitution reactions. This structural design ensures that the resulting PROTAC can effectively bridge the distance between the target protein and the ligase, a process critical for the degradation of proteins involved in cancer and other regulatory pathways. In conclusion, Pentaethylene glycol di(p-toluenesulfonate) is a high-quality synthetic building block essential for the development of potent and selective PROTAC degraders.
Keywords
Pentaethylene glycol di(p-toluenesulfonate), 41024-91-3, Penta(ethylene glycol) bis(p-toluenesulfonate), Bis-Tos-PEG5, PROTAC Linkers, Inhibitor, inhibitor, inhibit
References
**Background**
Folate is a critical B-vitamin essential for DNA synthesis, repair, and methylation. A deficiency in folate during early pregnancy is strongly linked to the development of neural tube defects (NTDs), while chronic deficiency in adults can lead to megaloblastic anemia. Because the body requires folate in its active form, L-5-methyltetrahydrofolate, the development of bioavailable supplements is crucial for maintaining optimal plasma and red blood cell folate levels. Research into folate-fortified preparations, such as certain oral contraceptives, has highlighted the importance of maintaining these levels to protect fetal development. In this context, we will introduce a brain-penetrant folate supplement – Levomefolate.
**Definition**
Levomefolate calcium is a synthetic calcium salt of L-5-methyltetrahydrofolate that serves as an orally active and brain-penetrant folate supplement. According to the Levomefolate technical information, it is designed to incorporate directly into body folate pools to increase systemic folate concentrations.
**In Vitro and In Vivo Studies**
The Levomefolate description specifies that this compound is utilized to increase plasma and red blood cell folate levels over time without significantly increasing folate concentrations in breast milk. Regarding Levomefolate in vitro application, it can be used to increase serum folate levels in contraceptive preparations to ensure optimal protection against neural tube defects. Furthermore, the compound is widely used in the research of megaloblastic anemia and the prevention of congenital anomalies. With a molecular weight of 497.52 and the Levomefolate Formula of C20H23CaN7O6, it provides a stable and effective means of supplementing the active form of folate. In conclusion, Levomefolate is a potent, brain-penetrant folate supplement suitable for research into hematological and developmental disorders.
Keywords
Levomefolate, 151533-22-1, Antifolate, neural tube defects, vitamin B12, red blood cell, folate, blood folate, L-5-methyltetrahydrofolate, breast milk, Inhibitor, inhibitor, inhibit
References
[1] Shere M, et al. The Effectiveness of Folate-Fortified Oral Contraceptives in Maintaining Optimal Folate Levels to Protect Against Neural Tube Defects: A Systematic Review. J Obstet Gynaecol Can. 2015;37(6):527-533.
[2] Plus Y. 1 INDICATIONS AND USAGE[J].
**Background**
Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders characterized by a deficiency in one of the enzymes required for the synthesis of cortisol in the adrenal cortex. This enzymatic blockade leads to an accumulation of precursor steroids and a subsequent increase in the secretion of adrenocorticotropic hormone (ACTH) via a negative feedback loop, further exacerbating the buildup of metabolites. Among these, the elevation of specific steroid precursors serves as a critical diagnostic marker for identifying the specific enzymatic defect. In particular, the measurement of plasma steroid levels is essential for the clinical diagnosis and monitoring of patients with CAH. In this context, we will introduce an endogenous metabolite used as a sign of congenital adrenal hyperplasia – 21-Deoxycortisol.
**Definition**
21-Deoxycortisol is a human endogenous metabolite belonging to the steroid classification. According to the 21-Deoxycortisol description, it serves as a key biochemical indicator for the diagnosis of congenital adrenal hyperplasia.
**Biological Activity**
As a steroid metabolite, 21-Deoxycortisol possesses a molecular weight of 346.46 and a specific 21-Deoxycortisol Formula of C21H30O4. In clinical research, the analysis of 21-Deoxycortisol biological activity and its concentration in plasma is utilized to differentiate between various forms of adrenal insufficiency. Specifically, elevated levels of 21-deoxycortisol, alongside 17-hydroxyprogesterone, are indicative of 21-hydroxylase deficiency, the most common cause of CAH. Researchers utilizing 21-Deoxycortisol in vitro assays can evaluate the metabolic pathways of steroidogenesis and the impact of enzymatic deficiencies on cortisol production. In conclusion, 21-Deoxycortisol is a vital endogenous steroid metabolite used as a diagnostic marker for congenital adrenal hyperplasia.
Keywords
21-Deoxycortisol, 641-77-0, Endogenous Metabolite, endogenous metabolite, congenital adrenal hyperplasia, sign, Inhibitor, inhibitor, inhibit
References
Early diagnosis of HIV infection remains a critical challenge in global public health, particularly due to the limitations of conventional testing methods in resource-limited settings. The p24-HIV protein serves as a reliable biomarker during the early phase of infection, before seroconversion occurs. This study reports the development of a disposable, label-free electrochemical aptasensor based on graphene quantum dot (GQD)-modified screen-printed electrodes (SPEs) for rapid, sensitive, and selective detection of p24-HIV at clinically relevant concentrations.
GQDs were synthesized through a simple thermal decomposition of citric acid at 200 °C, resulting in water-soluble nanoparticles with tunable optical and electronic properties. Characterization by TEM, SEM, and FTIR confirmed their nanoscale size (~7 nm), high surface area, and abundant carboxylic functional groups—ideal for bioconjugation. These GQDs were then deposited onto the working electrode of SPEs via electrochemical reduction under cyclic voltammetry conditions (−1.4 V to 0.0 V vs. Ag/AgCl), which reduced oxygenated species and enhanced adhesion while preserving electroactive sites.
Following deposition, the carboxylic groups on the GQD surface were activated using EDC/NHS chemistry, enabling covalent immobilization of amine-functionalized p24-specific DNA aptamers. A systematic optimization process identified 1 hour of activation and 2 hours of aptamer incubation as optimal, maximizing binding capacity without compromising specificity. Unreacted sites were blocked with bovine serum albumin (BSA), minimizing nonspecific adsorption.
The sensing mechanism relies on the suppression of redox current from K₃[Fe(CN)₆] upon specific binding of p24-HIV to the aptamer layer. The target-induced conformational change forms a non-conductive barrier that impedes electron transfer, leading to a measurable decrease in peak current proportional to analyte concentration. Under optimized conditions, the sensor exhibited a linear response over a broad dynamic range—from 0.93 ng mL⁻¹ to 93 μg mL⁻¹—with a correlation coefficient of 0.996. The limit of detection (LOD) was determined to be 51.7 pg mL⁻¹, demonstrating exceptional sensitivity suitable for early-stage diagnosis.
Selectivity was rigorously tested against p24-HTLV, a structurally similar viral antigen. No significant signal change was observed, confirming minimal cross-reactivity. The sensor also performed reliably in spiked human serum samples diluted 1:100, where a final concentration of 9.3 ng mL⁻¹ was clearly detected. The signal difference between positive and negative samples was distinct and reproducible, indicating low interference from biological matrix components.
Stability assessments revealed that the sensor retained over 92% of its initial response after four weeks of refrigerated storage, with less than 8% variation in baseline signal.5-tert-Butylisophthalic acid References After two weeks, detectability remained at 91% of the expected value, highlighting its potential for real-world deployment.Hesperetin manufacturer
This work demonstrates a scalable, low-cost, and highly effective strategy for point-of-care HIV screening.PMID:34113977 By leveraging the unique electrochemical advantages of GQDs within a disposable SPE platform, the developed aptasensor offers rapid, accurate, and field-deployable diagnostics—particularly valuable in regions lacking access to advanced laboratory infrastructure. Its ability to detect p24-HIV at ultra-low levels underscores its potential as a transformative tool in the fight against HIV, paving the way for future integration into portable, user-friendly diagnostic systems.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com